Quoin Pharmaceuticals Provides Product Portfolio Update

Lead Product, QRX003, Being Tested in Two Active Registrational Clinical Studies for Netherton Syndrome Across the U.S., Europe, and the Middle East.

QRX003 Peeling Skin Syndrome Clinical Program Continues Following Positive Initial Data

Read more at globenewswire.com